These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 14585851)
41. [Multi-drug resistance of serovar E strains in clinically isolated Pseudomonas aeruginosa and analysis of genome pattern]. Mogi T; Fukuchi K; Chen G; Wakuta R; Takagi T; Takagi Y; Gomi K Rinsho Byori; 1996 Feb; 44(2):147-52. PubMed ID: 8851198 [TBL] [Abstract][Full Text] [Related]
42. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates. Nazli E; Zer Y; Eksi F J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417 [TBL] [Abstract][Full Text] [Related]
43. [Combined in vitro effect of new betalactam antibiotics and aminoglycosides against Pseudomonas aeruginosa ]. Thabaut A; Durosoir JL; Meyran M Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):549-54. PubMed ID: 6812006 [TBL] [Abstract][Full Text] [Related]
44. Five-year report of national surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolated from non-tertiary care hospitals in Korea (2002-2006). Yoo J; Sohn ES; Chung GT; Lee EH; Lee KR; Park YK; Lee YS Diagn Microbiol Infect Dis; 2008 Mar; 60(3):291-4. PubMed ID: 18068936 [TBL] [Abstract][Full Text] [Related]
45. [The effect of the inoculum concentration on the in vitro sensitivity of Pseudomonas aeruginosa]. Zarakolu P; Cöplü N; Güvener E Mikrobiyol Bul; 1993 Jul; 27(3):211-5. PubMed ID: 8361409 [TBL] [Abstract][Full Text] [Related]
46. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa. Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466 [TBL] [Abstract][Full Text] [Related]
47. [Relationship between drug resistance of Pseudomonas aeruginosa isolated from burn wounds and its mobile genetic elements]. Hu XH; Xu XM; Mi ZH; Fan YF; Feng WY Zhonghua Shao Shang Za Zhi; 2009 Apr; 25(2):103-5. PubMed ID: 19799033 [TBL] [Abstract][Full Text] [Related]
48. Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms. Greenberg RN; Bollinger M; Compton J Clin Ther; 1986; 8(3):354-8. PubMed ID: 3087621 [TBL] [Abstract][Full Text] [Related]
50. [Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis]. Canis F; Husson MO; Vic P; Ategbo S; Turck D; Courcol R; Leclerc H Pathol Biol (Paris); 1995 Apr; 43(4):343-51. PubMed ID: 7567127 [TBL] [Abstract][Full Text] [Related]
51. [In vitro comparative activity of 4 beta-lactams against Pseudomonas aeruginosa. Role of cefoperazone]. Joly-Guillou ML; Bergogne-Berezin E; Verin-Prevost C Pathol Biol (Paris); 1984 May; 32(5):408-11. PubMed ID: 6429612 [TBL] [Abstract][Full Text] [Related]
52. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. Jung R; Fish DN; Obritsch MD; MacLaren R J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239 [TBL] [Abstract][Full Text] [Related]
53. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA; Gürler B J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946 [TBL] [Abstract][Full Text] [Related]
54. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital. Sasaki M; Hiyama E; Takesue Y; Kodaira M; Sueda T; Yokoyama T J Hosp Infect; 2004 Feb; 56(2):111-8. PubMed ID: 15019222 [TBL] [Abstract][Full Text] [Related]
55. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains. Drenjancević D; Vranes J; Bedenić B; Sakić-Zdravcević K Coll Antropol; 2007 Mar; 31(1):221-5. PubMed ID: 17598405 [TBL] [Abstract][Full Text] [Related]
56. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007 [TBL] [Abstract][Full Text] [Related]
57. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Japoni A; Alborzi A; Kalani M; Nasiri J; Hayati M; Farshad S Burns; 2006 May; 32(3):343-7. PubMed ID: 16527415 [TBL] [Abstract][Full Text] [Related]
58. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655 [TBL] [Abstract][Full Text] [Related]
59. [Antibiotic resistance and biofilm formation in Pseudomonas aeruginosa strains isolated from patients with urinary tract infections]. Cernohorská L; Sláviková P Epidemiol Mikrobiol Imunol; 2009 Nov; 58(4):154-7. PubMed ID: 21114003 [TBL] [Abstract][Full Text] [Related]